Company Overview and News

0
Big Read: Joanna Lawn, the savvy deal maker revamping the NZX

2018-07-15 nzherald.co.nz
When Joanna Lawn began her first job in a London financial dealing room, her boss almost kicked her out.
DB NZSTY NZSTF

0
QEX Logistics sees 42% revenue boost after listing

2018-07-12 nbr.co.nz
QEX Logistics has produced higher annual revenue than expected, as demand from China for milk powder and infant formula grows.
NZSTY NZSTF

4
PushPay in trading halt as Crowther sells $108m stake, exits

2018-06-18 nbr.co.nz
PushPay shares remain on a trading halt for a bookbuild to sell co-founder Eliot Crowther's 9.03% stake, valued at $108 million on the company's pre-halt price.
DB NZSTY NZSTF

4
Comment: Five steps to stronger capital markets

2018-06-10 nzherald.co.nz
If the New Zealand economy were a human body, then we can think of capital as the oxygen required to sustain life.
NZSTY NZSTF MSCI

0
Brian Gaynor: The NZX must take stock before it's left behind

2018-06-08 nzherald.co.nz
The World Federation of Exchanges (WFE), which was established in 1961 and is based in London, is the industry association for global stock exchanges and clearing houses.
ASXFF NZSTY ASXFY NZSTF

13
NZX 50 rises to record, led by F&P Healthcare

2018-06-06 nzherald.co.nz
New Zealand shares rose, pushing the S&P/NZX 50 Index to a record, as Fisher & Paykel Healthcare extended its gains and investors picked up stocks that are carrying a dividend payment including Ryman Healthcare, Mainfreight and Arvida Group.
FBU RHCGF NZSTY FBU FCREY RYHTY NZSTF RYM FRCEF SML

0
Mainfreight delivers record result as global reach expands

2018-05-29 nzherald.co.nz
Transport and logistics company Mainfreight has marked its 40th year in business with record full-year sales revenue of $2.62 billion - $2b of which was from overseas operations.
NZSTY NZSTF

1
NZX moving in new directions

2018-05-16 nzherald.co.nz
The future of NZ's capital markets lies in building on our economy's unique strengths and recognising the needs of local success stories — not in trying to match what other markets are doing.
PPL MRNRF PUPKY NZSTY NURPF NZSTF NEU

0
Time for NZ to grow FAANGs

2018-05-16 nzherald.co.nz
Their immense reach and intrusion into people's daily digital lives has sparked a backlash from consumers and regulators concerned about the exploitation of data.
WYN NZSTY NZSTF

0
NZX sells Farmers Weekly back to former owners

2018-05-15 nzherald.co.nz
NZX has sold its rural newspaper Farmers Weekly to its former owners Dean and Cushla Williamson for an undisclosed sum, with the new entity taking on all 15 staff.
NZSTY NZSTF

7
Brian Gaynor: Week brings bad news for the NZX

2018-04-13 nzherald.co.nz
It hasn't been a great week for the NZX, with the delisting of Trilogy International, Happy Valley Milk's decision to list on the ASX and Icebreaker's confirmed purchase price by US apparel giant VF Corp when an NZX listing was a potential alternative.
ASXFF NZSTY ANZLY AIR ASXFY NZSTF ANZFF ANZFY AIZ LGO

7
'Great shame' if Fletcher sold and delisted from NZX, says investment chief

2018-04-13 nzherald.co.nz
New Zealand investors would be much the poorer if Fletcher Building left the NZX, an investment expert said, and although the firm had issues, he does not want to see it follow a string of other businesses leaving our sharemarket.
FBU FBU NZSTY ADBCF ADLDY FCREY NZSTF FRCEF ABC

10
Shares keep falling amid global sell-off

2018-03-26 nzherald.co.nz
New Zealand's S&P/NZX 50 Index fell about 1 per cent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

10
MARKET CLOSE: NZ shares join global sell-off

2018-03-26 nbr.co.nz
(BusinessDesk) - New Zealand's S&P/NZX 50 Index fell about 1 percent for the second straight session, joining a global selloff that started on Wall Street and extended into Asia amid fears of a trade war. Spark NZ, Air New Zealand, Sky Network Television and A2 Milk all fell.
AIR ANZFY AIZ SKT SYKWF NZSTY ANZLY VTHPF NZSTF SKKTY ANZFF GTK SML AUG

16
MARKET CLOSE: NZ shares drop 1% on global selloff, US stocks wobble as Trump backs down on spending bill

2018-03-23 nbr.co.nz
New Zealand's NZX 50 Index dropped nearly 1 percent on global trade news in Friday trading., with Synlait Milk and Sky Network Television suffering while CBL remained in a trading halt as its administrators gained more time to consider its finances.
AIA WBC WEBNF WBK ACKDF AUKNY SKT GNE SYKWF NZSTY AIA WBC NZSTF SKKTY GNE MEZ GEL SML

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 629506106